L Laine

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial
    Loren Laine
    University of Southern California School of Medicine, Department of Medicine, Los Angeles 90033, USA
    Gastroenterology 127:395-402. 2004
  2. ncbi Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH
    S A Pais
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Aliment Pharmacol Ther 23:1607-13. 2006
  3. ncbi Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis
    Christopher P Cannon
    The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 152:237-45. 2006
  4. ncbi Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, University of Southern California, Keck School of Medicine, Los Angeles, California, USA
    Gastroenterology 135:1517-25. 2008
  5. ncbi Adherence to best practice guidelines in dyspepsia: a survey comparing dyspepsia experts, community gastroenterologists and primary-care providers
    B M R Spiegel
    Department of Gastroenterology, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
    Aliment Pharmacol Ther 29:871-81. 2009
  6. ncbi Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Am J Gastroenterol 107:379-86. 2012
  7. ncbi Gastric mucosal defense and cytoprotection: bench to bedside
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Gastroenterology 135:41-60. 2008
  8. ncbi Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Gastroenterology 134:1836-41. 2008
  9. ncbi COX-2 selective inhibitors in the treatment of osteoarthritis
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Semin Arthritis Rheum 38:165-87. 2008
  10. ncbi Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?
    L Laine
    Department of Medicine, U S C School of Medicine, Los Angeles, CA 90033, USA
    Aliment Pharmacol Ther 24:897-908. 2006

Detail Information

Publications68

  1. ncbi Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial
    Loren Laine
    University of Southern California School of Medicine, Department of Medicine, Los Angeles 90033, USA
    Gastroenterology 127:395-402. 2004
    ..We assessed the risk of ulcers with low-dose aspirin and the interaction of low-dose aspirin with a COX-2 selective inhibitor in a double-blind trial that compared placebo, low-dose aspirin, rofecoxib + low-dose aspirin, and ibuprofen...
  2. ncbi Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH
    S A Pais
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Aliment Pharmacol Ther 23:1607-13. 2006
    ..CONCLUSIONS: A dose of 120 mg of oral lansoprazole followed by standard 30 mg doses of lansoprazole every 3 h did not reliably sustain pH at the desired level of 6...
  3. ncbi Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis
    Christopher P Cannon
    The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 152:237-45. 2006
    ..The MEDAL program will help to better define the risk-to-benefit ratio of 2 NSAIDs, that differ in their selectivity for COX-2, notably diclofenac and etoricoxib...
  4. ncbi Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, University of Southern California, Keck School of Medicine, Los Angeles, California, USA
    Gastroenterology 135:1517-25. 2008
    ..Cyclo-oxygenase (COX)-2 selective inhibitors decrease upper GI events, but no prospective trial has prespecified assessment of lower GI clinical events...
  5. ncbi Adherence to best practice guidelines in dyspepsia: a survey comparing dyspepsia experts, community gastroenterologists and primary-care providers
    B M R Spiegel
    Department of Gastroenterology, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
    Aliment Pharmacol Ther 29:871-81. 2009
    ..Although 'best practice' guidelines for dyspepsia management have been disseminated, it remains unclear whether providers adhere to these guidelines...
  6. ncbi Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Am J Gastroenterol 107:379-86. 2012
    ....
  7. ncbi Gastric mucosal defense and cytoprotection: bench to bedside
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Gastroenterology 135:41-60. 2008
    ..Pharmacologic therapy with antisecretory drugs may be used in high-risk patients (eg, mechanical ventilation >or=48 hours), although the absolute risk reduction is small, and a decrease in mortality is not documented...
  8. ncbi Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Gastroenterology 134:1836-41. 2008
    ..If frequent oral dosing of PPIs provided similar antisecretory effect, this might be preferred based on ease and cost...
  9. ncbi COX-2 selective inhibitors in the treatment of osteoarthritis
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Semin Arthritis Rheum 38:165-87. 2008
    ....
  10. ncbi Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?
    L Laine
    Department of Medicine, U S C School of Medicine, Los Angeles, CA 90033, USA
    Aliment Pharmacol Ther 24:897-908. 2006
    ..When determining whether low-dose aspirin is appropriate for an individual patient, the cardiovascular benefit must be weighed against the potential for clinical events such as gastrointestinal bleeding...
  11. ncbi Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs
    L Laine
    Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, CA 90033, USA
    Aliment Pharmacol Ther 24:751-67. 2006
    ..Lower gastrointestinal effects of non-steroidal anti-inflammatory drugs (NSAIDs) are much more poorly characterized than upper gastrointestinal effects...
  12. ncbi GI risk and risk factors of NSAIDs
    Loren Laine
    GI Division, Department of Medicine, University of Southern California School of Medicine, Los Angeles, CA 90033, USA
    J Cardiovasc Pharmacol 47:S60-6. 2006
    ..Strategies employed include the use of non-NSAID analgesics, use of lowest effective dose of NSAID, use of medical cotherapy (eg, proton pump inhibitor, misoprostol), or use of coxibs...
  13. ncbi Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Lancet 369:465-73. 2007
    ..Our aim was to assess the effects of these drugs on gastrointestinal outcomes in a population that includes patients taking gastrointestinal protective therapy...
  14. ncbi Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies
    L Laine
    University of Southern California, Los Angeles, 90033, USA
    Aliment Pharmacol Ther 33:203-12. 2011
    ..Current PPIs may not achieve desired outcomes in some GERD patients due to limited duration of acid inhibition...
  15. ncbi Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 7:33-47; quiz 1-2. 2009
    ..Bolus followed by continuous-infusion intravenous proton pump inhibitor should be used after endoscopic therapy...
  16. ncbi Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients
    L Laine
    University of Southern California, Los Angeles, CA 90033, USA
    Aliment Pharmacol Ther 32:1240-8. 2010
    ..Nonsteroidal anti-inflammatory drugs (NSAID)-related GI effects vary based on patient characteristics...
  17. ncbi Randomized trial of urgent vs. elective colonoscopy in patients hospitalized with lower GI bleeding
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Am J Gastroenterol 105:2636-41; quiz 2642. 2010
    ....
  18. ncbi Does capsule endoscopy improve outcomes in obscure gastrointestinal bleeding? Randomized trial versus dedicated small bowel radiography
    Loren Laine
    Division of Gastrointestinal and Liver Disease, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Gastroenterology 138:1673-1680.e1; quiz e11-2. 2010
    ..Capsule endoscopy improves the diagnostic yield in patients with obscure gastrointestinal (GI) bleeding, but whether it improves outcomes is uncertain...
  19. ncbi Methodology for randomized trials of patients with nonvariceal upper gastrointestinal bleeding: recommendations from an international consensus conference
    Loren Laine
    Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Am J Gastroenterol 105:540-50. 2010
    ..In general, the primary population for analysis is all patients randomized, although a per-protocol population may be used if this is the more conservative approach (e.g., equivalence study)...
  20. ncbi Proton pump inhibitor and clopidogrel interaction: fact or fiction?
    Loren Laine
    University of Southern California, Los Angeles, 90033, USA
    Am J Gastroenterol 105:34-41. 2010
    ..PPI may be given before breakfast and clopidogrel at bedtime, or PPI may be taken before dinner and clopidogrel at lunchtime...
  21. ncbi Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines
    L Laine
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Aliment Pharmacol Ther 30:767-74. 2009
    ..Protective co-therapy is recommended in NSAID users with GI risk factors, but adherence is poor...
  22. ncbi Proton pump inhibitors and bone fractures?
    Loren Laine
    Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Am J Gastroenterol 104:S21-6. 2009
    ..As with all medications, PPIs should be used for appropriate indications and not in higher doses or longer durations than necessary to achieve the desired outcomes...
  23. ncbi How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial
    Loren Laine
    University of Southern California, Los Angeles, California 90033, USA
    Am J Gastroenterol 104:356-62. 2009
    ..We determined the rate of laboratory and clinical adverse hepatic effects in a large double-blind trial of diclofenac...
  24. ncbi Is it time for quadruple therapy to be first line?
    Loren Laine
    Gastrointestinal Division, Department of Medicine, University of Southern California School of Medicine, 2025 Zonal Avenue, Los Angeles, CA 90033, USA
    Can J Gastroenterol 17:33B-35B. 2003
    ..Therefore, quadruple therapy can be considered a first line therapy for H pylori...
  25. ncbi Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs
    Loren Laine
    Department of Medicine, U S C School of Medicine, 2025 Zonal Avenue, Los Angeles, California 90033, USA
    Gastroenterology 125:389-95. 2003
    ..chronic coxib therapy in a U.S. administrative claims database of >8 million lives...
  26. ncbi Review article: the effect of Helicobacter pylori infection on nonsteroidal anti-inflammatory drug-induced upper gastrointestinal tract injury
    L Laine
    Gastrointestinal Division, University of Southern California School of Medicine, Los Angeles, CA 90033, USA
    Aliment Pharmacol Ther 16:34-9. 2002
    ..Both NSAIDs and H. pylori are independent risk factors for ulcer disease. Therefore, in an individual patient with an ulcer, one cannot be certain which factor is responsible for the ulcer, and both risks should be removed if possible...
  27. ncbi Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use
    Loren Laine
    University of Southern California School of Medicine, Los Angeles 90033, USA
    Gastroenterology 124:288-92. 2003
    ..We performed a post hoc analysis of serious lower GI clinical events with a nonselective NSAID and a COX-2-selective agent in a prospective, double-blind, randomized GI outcomes trial...
  28. ncbi Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial
    L Laine
    Gastrointestinal Division, University of Southern California School of Medicine, 2025 Zonal Avenue, Los Angeles, CA 90033, USA
    Aliment Pharmacol Ther 16:1143-8. 2002
    ..This prospective study was designed to assess reflux-related quality of life and the symptoms of gastro-oesophageal reflux disease in patients undergoing H. pylori therapy...
  29. ncbi Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient
    L Laine
    University of Southern California School of Medicine, Los Angeles, California 90033, USA
    Gastroenterology 120:594-606. 2001
    ..This review discusses the risks of clinical GI disease in NSAID users, the predictors of increased risk, and strategies for prevention of NSAID-associated GI disease...
  30. ncbi Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors
    L Laine
    University of Southern California School of Medicine, Los Angeles, California 90033, USA
    Aliment Pharmacol Ther 14:651-68. 2000
    ..Nevertheless, continued follow-up of patients taking proton pump inhibitors for extended periods will provide greater experience regarding the potential gastrointestinal adverse effects of long-term acid suppression...
  31. ncbi Review article: esomeprazole in the treatment of Helicobacter pylori
    L Laine
    Department of Medicine, University of Southern California School of Medicine, Los Angeles, CA 90033, USA
    Aliment Pharmacol Ther 16:115-8. 2002
    ..Thus, esomeprazole triple therapy with amoxicillin and clarithromycin is effective in the treatment of H. pylori, with eradication rates comparable to previously studied proton pump inhibitor-based triple therapies...
  32. ncbi A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group
    L Laine
    Division of Gastrointestinal Diseases, University of Southern California, Los Angeles, California, USA
    Gastroenterology 117:776-83. 1999
    ....
  33. ncbi Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis
    Loren Laine
    University of Southern California School of Medicine, Los Angeles, California 90033, USA
    Gastroenterology 123:1006-12. 2002
    ....
  34. ncbi Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy
    L Laine
    U S C School of Medicine, Los Angeles, California 90033, USA
    Aliment Pharmacol Ther 12:887-92. 1998
    ..Patients with persistent Helicobacter pylori infection following treatment with clarithromycin or omeprazole plus clarithromycin often develop clarithromycin resistance...
  35. ncbi Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a
    Loren Laine
    University of Southern California School of Medicine, Los Angeles, CA 90033, USA
    Am J Gastroenterol 98:562-7. 2003
    ..pylori eradication. This OBMT therapy largely overcomes H. pylori metronidazole resistance, present in 40% of patients in this study...
  36. ncbi The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors
    Loren Laine
    Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Semin Arthritis Rheum 32:25-32. 2002
    ..In addition, 2 large outcome trials indicated that coxibs can also reduce the incidence of clinically important GI events...
  37. ncbi The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms
    Loren Laine
    Gastrointestinal Division, Department of Medicine, University of Southern California School of Medicine, Los Angeles, California, USA
    Rev Gastroenterol Disord 3:S30-9. 2003
    ....
  38. ncbi Evaluating the process of care in nonvariceal upper gastrointestinal haemorrhage: a survey of expert vs. non-expert gastroenterologists
    E Esrailian
    VA Greater Los Angeles Healthcare System, Los Angeles, California, USA
    Aliment Pharmacol Ther 28:1199-208. 2008
    ..Aim To perform a survey to measure the process of care and variations in decision-making in nonvariceal upper gastrointestinal tract haemorrhage (NVUGIH) and compare results between experts and non-experts...
  39. ncbi Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials
    L Laine
    Gastrointestinal Division, Department of Medicine, University of Southern California School of Medicine, 2025 Zonal Avenue, Los Angeles, CA 90033, USA
    Ann Intern Med 134:361-9. 2001
    ..17 (CI, 0.87 to 1.59) without heterogeneity. CONCLUSION: This meta-analysis provides little support for the use of H. pylori eradication therapy in patients with nonulcer dyspepsia...
  40. ncbi Gastrointestinal safety of coxibs and outcomes studies: what's the verdict?
    Loren Laine
    GI Division, Department of Medicine, University of Southern California School of Medicine, Los Angeles, CA 90033, USA
    J Pain Symptom Manage 23:S5-10; discussion S11-4. 2002
    ..A subgroup analysis in the patients who did not take aspirin revealed a nonsignificant 45% reduction in complicated events with celecoxib (P = 0.19), and a 47% reduction in complicated and symptomatic ulcers (P = 0.02)...
  41. ncbi Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, Department of Medicine, University of Southern California School of Medicine, Los Angeles, California, USA
    Rev Gastroenterol Disord 4:S33-41. 2004
    ..Patients taking low-dose aspirin who have risk factors for GI complications (including concomitant nonselective NSAID therapy) should receive medical co-therapy, such as a PPI...
  42. ncbi Gastrointestinal effects of NSAIDs and coxibs
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, University of Southern California School of Medicine, Los Angeles, CA, USA
    J Pain Symptom Manage 25:S32-40. 2003
    ..The cost-effectiveness of coxibs increases (the cost per GI event averted decreases) in patients with high-risk clinical features because they have higher rates of GI hospitalizations and greater use of expensive prophylactic co-therapy...
  43. ncbi The utility of intraluminal impedance in patients with gastroesophageal reflux disease-like symptoms but normal endoscopy and 24-hour pH testing
    Michael M Kline
    Department of Medicine, Division of Gastroenterology, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Clin Gastroenterol Hepatol 6:880-5; quiz 836. 2008
    ..We aimed to determine whether the Symptom Index (SI) obtained using MII-pH identified an association of symptoms with reflux events in nonclassic acid-reflux disease...
  44. ncbi Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis
    Joshua J Ofman
    Department of Medicine, Zynx Health-A Cerner Company, Beverly Hills, California 90212, USA
    Am J Med 116:835-42. 2004
    ....
  45. ncbi Randomized trial of normal saline solution injection versus bipolar electrocoagulation for treatment of patients with high-risk bleeding ulcers: is local tamponade enough?
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, USC School of Medicine, Los Angeles, California 90033, USA
    Gastrointest Endosc 55:6-10. 2002
    ..If it is as effective as standard therapy, low cost, wide availability, and lack of injury would make saline solution injection an attractive option...
  46. ncbi Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies
    Loren Laine
    Department of Medicine, University of Southern California School of Medicine, Los Angeles, California 90033, USA
    Am J Gastroenterol 97:2992-7. 2002
    ..pylori eradication in patients with duodenal ulcer disease leads to the development of erosive esophagitis, the development of new symptomatic GERD, or worsening of symptoms in patients with pre-existing GERD...
  47. ncbi Systematic review of the predictors of recurrent hemorrhage after endoscopic hemostatic therapy for bleeding peptic ulcers
    B Joseph Elmunzer
    Division of Gastroenterology, Department of Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Am J Gastroenterol 103:2625-32; quiz 2633. 2008
    ..The aim of this systematic review was to identify the strongest and most consistent predictors of rebleeding to assist in the development of tools to stratify and appropriately manage patients after endoscopic therapy...
  48. ncbi Optimizing bipolar electrocoagulation for endoscopic hemostasis: assessment of factors influencing energy delivery and coagulation
    Loren Laine
    Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Gastrointest Endosc 67:502-8. 2008
    ..Few data inform decisions on the optimal bipolar electrocoagulation (BPEC) technique...
  49. ncbi Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials
    Kenneth R McQuaid
    Department of Medicine, University of California San Fransisco, CA, USA
    Clin Gastroenterol Hepatol 3:553-63. 2005
    ..Proton pump inhibitors (PPIs) are often taken for short-term treatment of heartburn. We performed a systematic review of the efficacy of PPIs for heartburn relief within the first 1-2 days of therapy...
  50. ncbi A systematic review and meta-analysis of randomized, controlled trials of moderate sedation for routine endoscopic procedures
    Kenneth R McQuaid
    Veterans Affairs Medical Center and Department of Medicine, University of California San Francisco, California, USA
    Gastrointest Endosc 67:910-23. 2008
    ..Numerous agents are available for moderate sedation in endoscopy...
  51. ncbi Cytomegalovirus infection in patients with active inflammatory bowel disease
    John J Kim
    Department of Medicine, Keck School of Medicine University of Southern California, Los Angeles, CA, USA
    Dig Dis Sci 55:1059-65. 2010
    ..The reported prevalence of cytomegalovirus (CMV) infection with active inflammatory bowel disease (IBD) is highly variable, and whether CMV negatively impacts the clinical course is controversial...
  52. ncbi The cost-effectiveness of competing strategies for the prevention of recurrent peptic ulcer hemorrhage
    Joshua Ofman
    Zynx Health, Subsidiary of Cedars-Sinai Health System, Beverly Hills, California 90212, USA
    Am J Gastroenterol 97:1941-50. 2002
    ..pylori are cost-effective for the prevention of recurrent ulcer-related hemorrhage because they maximize H. pylori detection and eradication, resulting in fewer recurrent hemorrhages and fewer patients requiring antisecretory therapy...
  53. ncbi Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients
    Steven A Conrad
    Louisiana State University, Shreveport, LA, USA
    Crit Care Med 33:760-5. 2005
    ..CONCLUSIONS: Immediate-release omeprazole suspension is effective in preventing upper gastrointestinal bleeding and more effective than intravenous cimetidine in maintaining gastric pH of >4 in critically ill patients...
  54. ncbi Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients
    Alaa Rostom
    University of Ottawa, Ontario, Canada
    Clin Gastroenterol Hepatol 3:489-98. 2005
    ..CONCLUSIONS: Diclofenac and rofecoxib had higher rates of aminotransferase elevations than placebo and other NSAIDs studied. No NSAID studied had increased rates of liver-related serious adverse events, hospitalizations, or deaths...
  55. ncbi Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials
    Nimish Vakil
    University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin and Marquette University College of Health Sciences, Milwaukee, Wisconsin 53233, USA
    Am J Gastroenterol 103:1906-19. 2008
    ..Therapies for dysmotility-like functional dyspepsia (FD) are limited. We studied tegaserod, a selective serotonin type 4 receptor agonist, in patients with FD...
  56. ncbi Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Lancet 368:1771-81. 2006
    ..The MEDAL programme was designed to provide a precise estimate of thrombotic cardiovascular events with the COX-2 selective inhibitor etoricoxib versus the traditional NSAID diclofenac...
  57. ncbi Response to expression of concern regarding VIGOR study
    Claire Bombardier
    N Engl J Med 354:1196-9. 2006
  58. ncbi Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed
    Geoffrey C Schreiner
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Crit Pathw Cardiol 6:169-72. 2007
    ..The use of PPI in routine practice is not well defined, especially in patients with acute coronary syndromes (ACS) who require one or several antithrombotic drugs...
  59. ncbi Controversies in COX-2 selective inhibition
    Lee S Simon
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Rheumatol 29:1501-10. 2002
  60. ncbi Management of ulcers with adherent clots
    Loren Laine
    Gastroenterology 123:632-6. 2002
  61. ncbi Considerations in the management of steroid-dependent Crohn's disease
    Loren Laine
    Sectioin of Gastroenterology and Nutrition, University of Chicago, Chicago, Illinois 60637, USA
    Gastroenterology 125:906-10. 2003
  62. ncbi Treatment of nonvariceal upper GI hemorrhage: what's happening in the real world
    Loren Laine
    Am J Gastroenterol 99:1247-9. 2004
  63. ncbi Esophageal capsule endoscopy for screening and surveillance of esophageal varices in patients with portal hypertension
    Roberto de Franchis
    Department of Medical Sciences, University of Milan, Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Ospedale Maggiore Policlinico, Mangiagalli and Regina Elena, Milan, Italy
    Hepatology 47:1595-603. 2008
    ..However, the minimal invasiveness, good tolerance, and good agreement of capsule endoscopy with EGD might increase adherence to screening programs. Whether this is the case needs to be determined...
  64. ncbi Endoscopic therapy for bleeding ulcers: room for improvement?
    Loren Laine
    Gastrointest Endosc 57:557-60. 2003
  65. ncbi Bleeding complications related to aspirin dose
    Loren Laine
    Am J Cardiol 96:1035-6. 2005
  66. ncbi Systematic review of endoscopic therapy for ulcers with clots: Can a meta-analysis be misleading?
    Loren Laine
    Gastroenterology 129:2127; author reply 2127-8. 2005
  67. ncbi Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials
    Kenneth R McQuaid
    Veterans Affairs Medical Center, San Francisco, CA 94121, USA
    Am J Med 119:624-38. 2006
    ..We performed a systematic review to define the relative and absolute risk of clinically relevant adverse events with the antiplatelet agents, aspirin and clopidogrel...
  68. ncbi A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience
    Lawrence Goldkind
    Uniformed Services University for Health Sciences Bethesda, MD 20854, USA
    Pharmacoepidemiol Drug Saf 15:213-20. 2006
    ..Therefore, it remains critical that clinicians report such cases to the FDA through the MEDWATCH system and that active post-marketing monitoring studies be used to identify potential rare cases of hepatotoxicity...